Skip to Main Content

To say this past year has been like no other is an understatement. But for the pharmaceutical industry, 2020 has been something of a defining moment.

After being in the crosshairs over pricing, drug companies were suddenly seen as lifeboats that could rescue the world from the Covid-19 pandemic.

advertisement

The sudden turn of events has cast the industry in a different light, but arguably, may not have changed its fortunes in the long run. The pandemic has thrown into sharp relief the debate over profits, innovation, and intellectual property rights on one side, and affordability and access on the other. And 2021 may prove to be a moment of reckoning for all concerned.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.